Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

News Conference News TCT 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

Yael L. Maxwell

September 21, 2022

FAVOR III China: Early Gains of QFR in PCI Persist to 2 Years

News Conference News TCT 2022

FAVOR III China: Early Gains of QFR in PCI Persist to 2 Years

September 20, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

A Clinical Cardiologist’s View on How to Choose Revascularization Strategies

Presentation TCT 2022

A Clinical Cardiologist’s View on How to Choose Revascularization Strategies

Presenter: Patrick O'Gara

September 18, 2022

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

News Conference News TCT 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

November 11, 2021

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

October 25, 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

News Conference News TCT 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

October 22, 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

News Conference News TCT 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

Michael O'Riordan

October 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.